Forbes November 21, 2023
The FDA recently approved Zepbound, a weekly injectable drug targeted to treat obesity. The medication contains tirzepatide, the same active ingredient that is also present in the diabetes drug Mounjaro.
People with obesity who took the highest dose of the drug lost 21 percent of their total body weight, according to a randomized-controlled trial published in the New England Journal of Medicine. This could be welcoming news for the one billion people around the world struggling with this condition, not to mention the 100 million Americans affected by it, according to CDC data.
The newly approved drug works by mimicking two naturally occurring hormones in the body, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 stimulates the pancreas to...
Today's Sponsors
Today's Sponsor